News 2024.12.25 Press Release iXgene and C4U Partner on Collaborative Research for CRISPR-Cas3 Genome Editing Technology 2024.09.02 Announcement We moved our office. 2024.02.09 Announcement iXgene Inc. signs License Agreement with Keio University Educational Corporation for Commercialization of Suicide Gene Transfer iPS Cell Patents 2023.10.10 Press Release Announcement of a three-way joint research agreement between iXgene, Keio University School of Medicine, and Sumitomo Pharma for the practical application of a treatment for malignant brain tumors using genome-edited iPS cells. 2023.01.05 Press Release Keio Innovation Initiative/University of Tokyo Collaborative Creation Platform Development/MSF Capital Partners/Green Core to carry out third-party allotment capital increase totaling 600 million yen
